Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-GRPR
- Development stage
- Unknown
- Lead developer
- Advanced Accelerator Applications
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
68Ga-GRPR refers to a class of Gallium-68 labeled radiopharmaceuticals that target the gastrin-releasing peptide receptor (GRPR), which is overexpressed in various cancers, including prostate, breast, and gastrointestinal stromal tumors (GIST). These agents function as diagnostic imaging tracers for positron emission tomography (PET) or PET/computed tomography (PET/CT) and PET/magnetic resonance imaging (PET/MRI). The class includes several specific GRPR antagonists and agonists, such as 68Ga-RM2, 68Ga-RM26, 68Ga-SB3, and 68Ga-NeoBOMB1. Upon administration, the peptide moiety of the tracer binds with high affinity to GRPR on tumor cells, allowing for high-contrast visualization of primary tumors and metastatic lesions. 68Ga-GRPR imaging is particularly valuable as a complementary diagnostic tool to PSMA-targeted imaging in prostate cancer, especially for low-grade or PSMA-negative tumors, and for staging estrogen receptor-positive (ER+) breast cancer.
- Other names
- 68Ga-GRPR antagonist68Ga-GRPR ligand68Ga-GRPR tracer68Ga-labeled gastrin-releasing peptide receptor antagonist68Ga-labeled GRPR antagonist68Ga-labeled GRPR ligandGa-68 GRPRGa68 GRPRGa 68 GRPR
02
Targets
GRPR (Gastrin-releasing peptide receptor)
Beyond the preview
Go deeper on 68Ga-GRPR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-GRPR.